期刊文献+

氯吡格雷抵抗与血瘀证关系分析 被引量:7

The Relationship Analysis of Clopidogrel Resistance and Blood Stasis Syndrome
在线阅读 下载PDF
导出
摘要 目的:探讨不同程度血瘀证与生化氯吡格雷抵抗(CR)及临床CR的关系。方法:收集2008年1月~2009年6月连续住院的中国汉族心脑动脉血栓性疾病患者365例,其中男235例,女130例,平均年龄67.12±9.12岁,比较不同程度血瘀证与生化CR(即ADP诱导的最大血小板聚集率(MPA)在氯吡格雷治疗10天后比服药前下降≤10%)和临床CR(PCI术后心血管事件再发)之间的关系。结果:(1)在365例心脑动脉血栓性疾病的患者中,重度血瘀证组患者在服氯吡格雷后,MPA下降的幅度为10.58%±9.19%,明显小于轻度血瘀证组(17.50%±8.85%,P<0.01);(2)在365例心脑动脉血栓性疾病的患者中,重度血瘀证组中出现生化CR的患者人数为132例,占64.4%,明显高于轻度血瘀证组31例(占19.4%,P<0.01);(3)在130例行PCI患者中,重度血瘀证组心脑血管事件再发人数为29例,占46.8%,明显高于轻度血瘀证组12例(占17.6%,P<0.01)。结论:不同程度的血瘀证不仅与生化CR密切相关,而且增加了中国汉族PCI术后患者心血管事件再发的危险。 Object:To explore the relationship among valying degree of blood stasis syndrome ,biochemical clopidogrel resistance (CR) and clinical CR . Method:Collect 365 Han Chinese patients with cardiovascular and cerebrovascular disease who was hospitalized in January 2008 - June 2009. Of whic, h 235 cases of male, 130 cases of women,The average age is 67. 12 ±9. 12years. Compare varying degree of blood stasis syndrome to biochemical CR ( Maximum platelet aggregation rate That ADP-induced decreases less than 10% after clopidogrel treatment in ten days )and clinical CR( cardiovascular events recurrent after PCI). Resuhs:l. In 365 cases of ischemic cardiovascular and cerebrovaseular disease patients,after patients with severe blood stasis syndrome served clopidogrel, the decreasing rate of MPA significantly is greater than that in mild blood stasis syndrome group;2 In 365 cases of ischemie cardiovascular and cerebrovascular disease patients,there are 132 patients with severe blood stasis syndrome who have biochemical CR. The rate is 64. 4% , which is higher than that of mild blood stasis syndrome group. 3. In 365 cases of patients undergoing percutaneous coronary intervention (PCI) ,there are 29 patients undergoing cardiovascular and cerebrovascular events (46. 8% ) ,which is higher than mild blood stasis syndrome group. Conclusion:Varying degree blood stasis syndrome has relationship with biochemical CR ,and increases risk of cardiovascular events recurrence after PCI in Chinese Han patients.
出处 《江西中医学院学报》 2009年第5期63-65,共3页 Journal of Jiangxi College of Traditional Chinese Medicine
基金 卫生部科学研究基金福建省卫生教育联合攻关计划项目(WKJ2008-2-59)
关键词 中医证型 血瘀证 氯吡咯雷抵抗(CR) TCM syndrome Blood stasis syndrome Clopidogrel resistance(CR)
  • 相关文献

参考文献14

  • 1Gurbel PA,Bliden KP,Hiatt BL,et all Clopidogrel for coronary stenting: Response varisbility, drug resistance, and the effect of pretreatment platelet reactivity[ J]. Circulation ,2003,107:2 908 - 2 913.
  • 2郑少平,徐秀英.氯吡格雷抵抗[J].基础医学与临床,2006,26(11):1270-1275. 被引量:1
  • 3陈可冀,李连达,翁维良.血瘀证与活血化瘀研究[J].中西医结合心脑血管病杂志,2005,3(1):1-2. 被引量:245
  • 4刘幼文,左辉华,刘强,金光临,罗剑峰,曾繁芳,师姗姗,周淑英.择期冠状动脉介入治疗患者氯吡格雷抵抗现象的观察[J].中国循环杂志,2007,22(5):333-336. 被引量:2
  • 5李俭强,杨树森,樊瑛,常惠颖.氯吡格雷抵抗——不可忽视的临床问题[J].中国介入心脏病学杂志,2007,15(1):52-55. 被引量:4
  • 6Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin redueesthe ability of clopidogrel to inhibit platelet aggregation : a new drug - drug interactionl Circulation ,2003,107:32 - 37.
  • 7Fontana P, Dupont A, Gandrille S,et al. Adenosine diphos-phate-induced platelet aggregation is associated with P2YI2 gene sequence variations in healthy subjectsl Circulation,2003,108:989 - 995.
  • 8LauWC, Gurbel PA, Watkins P.B, et al. Contribution of hepatic cytochrome 17450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation ,2004,109 : 166 - 171.
  • 9Hechler B, Zhang Y, Eckly A,et al. Lineage-specific over-expression of the P2Y1 receptor induces platelct hyper-reactivity in transgenic mice. J Thromb Haemost,2003,1 : 155 - 163.
  • 10Fontana P,Gaussem P,AiachM,et al. P2YI2 H2 haplo type is associated with peripheral arterial disease:a case-control study. Circulation ,2003,108:2 971 - 2 973.

二级参考文献95

  • 1Mitsios JV,Papathanasiou AI,Rodis FI,et al.Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes[J].Circulation,2004,109:1335-1338.
  • 2Serebruany VL,Midei MG,Malinin AI,et al.Absence of interaction between atorvastatin or other statins and clopidogrel:results from the interaction study[J].Arch Intern Med,2004,164:2051 -2057.
  • 3Piokowski M,Weikert U,Schwimmbeck PL,et al.ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin[J].Thromb haemost,2004,92:614-620.
  • 4Mukherjee D,Kline-rogers E,Fang J,et al.Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome[J].Heart,2005,91:23-26.
  • 5Saw J,Steinhubl SR,Berger PB,et al.Lack of adverse clopidogrelatorvastatin clinical interaction from secondary analysis of a randomized,placebo-controlled clopidogrel trial[J].Circulation,2003,108:921 -924.
  • 6Wienbergen H,Gitt AK,Schiele R,et al.Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J].Am J Cardiol,2003,92:285 -288.
  • 7Muller I,Besta F,Schulz C,et al.Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J].Circulation,2003,108:2195 -2197.
  • 8Gorchakova O,yon Beckerath N,Gawaz M,et al.Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting[J].Eur Heart J,2004,25:1898 -1902.
  • 9Lidell C,Svedberg LE,Lindell P,et al.Clopidogrel and warfarin:absence of interaction in patients receiving longterm anticoagulant therapy for non-vavular atrial fibrillation[J].Thromb Haemost,2003,89:842-846.
  • 10Talreja D,Lubbe D,Orford JL,et al.Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein Ⅱ b/Ⅲ a inhibitor has been given? insight from an optical platelet aggregometry study[J].J Thromb Thrombolysis,2004,18(1):25 -30.

共引文献254

同被引文献80

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部